Invokana Lawsuit Observe Diabetes Type-2 Drug’s Potential Link To Kidney Failure

April 20, 2016 – – TheProductLawyers.com comment upon alarming released reports which indicate that new-generation diabetes drug, Invokana has been implicated in causing serious renal impairment. Impacted patients who were using the drug made adverse event reports the to the U.S. Food and Drug Administration. It was noted that the FDA received 50 of these adverse event reports containing patient claims of acquired development of renal impairment and kidney failure. These serious reports were filed within the drug’s first year on the market.

In 2013, Invokana gained FDA approval to treat type-2 diabetes patients and was released to the pharmaceutical market. Invokana assists patients in managing their blood sugar (glucose) levels. To achieve this, Invokana blocks the kidneys from reabsorbing extra blood sugar in the body, and instead eliminates extra sugar through the renal system. Invokana was released to the market as the first of a group of drugs classed as SGLT2 inhibitors. This abbreviation stands for sodium-glucose cotransporter-2.

Invokana invokes a metabolic action which places additional strain upon kidney function. Resultantly, there is a greater potential for excess stress upon and damage to the kidneys. Patients with diabetes are predisposed to renal complications. Patients with pre-existing kidney problems may be at greater risk of suffering additional damage to these important organs.

On December 4, 2015, The U.S. Food and Drug Administration issued a public safety warning announcing that they were requiring important label warning adjustments for Invokana products. Required changes were to be made by Invokana manufacturer, Janssen Pharmaceuticals, a division of well-known Johnson & Johnson corporation. At this time, the FDA had already received 19 adverse event reports from patients who claimed to have developed acute life-threatening complications after taking the drug.

These complications, it is alleged presented initially as urinary tract infections (UTIs) which then progressed to become blond kidney infections. The reports indicated that every one of the 19 patients discussed required emergency hospital admission and renal dialysis, a complex treatment for advanced kidney failure. Damage acquired by kidneys is permanent. Adversely impacted patients with substantially damaged kidneys require life-saving kidney transplants.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009437